Century Therapeutics (IPSC) Long-Term Investments (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Long-Term Investments data on file, last reported at $82.2 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $82.2 million, up 296.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $82.2 million (up 296.7% YoY), and the FY2024 annual result was $30.8 million, down 65.41% from the prior year.
• Long-Term Investments grew to $82.2 million in Q1 2026 per IPSC's latest filing, from $2.7 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $144.6 million in Q2 2023 and troughed at $2.7 million in Q2 2025.
• A 5-year average of $66.2 million and a median of $57.9 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2025 and 2026: Long-Term Investments sank 96.33% in 2025, then jumped 296.7% in 2026.
• A 5-year view of Long-Term Investments shows it stood at $51.9 million in 2022, then surged by 71.82% to $89.1 million in 2023, then slumped by 65.41% to $30.8 million in 2024, then slumped by 91.27% to $2.7 million in 2025, then soared by 2954.61% to $82.2 million in 2026.
• Business Quant data shows IPSC's Long-Term Investments at $82.2 million in Q1 2026, $2.7 million in Q2 2025, and $20.7 million in Q1 2025.